Cocrystal Pharma, Inc. announced that it has entered into an exclusive license and collaboration agreement with Merck to discover and develop certain proprietary influenza A/B antiviral agents. Under the terms of the agreement, Merck will fund research and development for the program, including clinical development, and will be responsible for worldwide commercialization of any products derived from the collaboration. Cocrystal will be paid an undisclosed upfront sum and is eligible to receive payments related to designated development, regulatory and sales milestones with the potential to earn up to $156 million, as well as undisclosed royalties on product sales.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.27 USD | +1.34% | -2.16% | +31.81% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+31.81% | 2.28Cr | |
+20.17% | 13TCr | |
+24.67% | 12TCr | |
+25.44% | 2.77TCr | |
-17.74% | 2.03TCr | |
-15.17% | 1.68TCr | |
-15.21% | 1.56TCr | |
+11.91% | 1.48TCr | |
-47.10% | 1.46TCr | |
+54.50% | 1.44TCr |
- Stock Market
- Equities
- COCP Stock
- News Cocrystal Pharma, Inc.
- Cocrystal Pharma Announces Exclusive Worldwide License and Collaboration Agreement with Merck